Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA coming out with PR saying they have a vaccine for Corona. Somebody refresh my memory because this is the same company that pulled the same stunt with Zika? Anytime something comes out, they rush out a press release that they have a cure?
Moderna Stock Surges as Wall Street Gives Thumbs Up to Vaccine Data -- Barrons.com 10:13 am ET July 15, 2020 (Dow Jones) Print By Josh Nathan-Kazis Analysts are finally getting a look at the results from Moderna's Phase 1 trial of its Covid-19 vaccine, and they say the data looks pretty good. The trial data, published Tuesday evening in the New England Journal of Medicine, comes two months after Moderna (ticker: MRNA) issued a press release claiming that results from the study had been positive, while offering little evidence. "We see this as strong initial data for mRNA-1273 and expect MRNA higher on these results which confirm the initial PhI press release," wrote Morgan Stanely analyst Matthew Harrison in a note out late Tuesday night. The New England Journal paper reported that the vaccine induced immune responses to the virus that causes Covid-19 in all trial participants. Participants who received 100 microgram doses of the vaccine, which Moderna has selected to use in the Phase 3 trial, produced neutralizing antibodies after a booster dose at a level four times higher than the study found in the blood of three patients who had recovered from Covid-19 infections. Shares of Moderna were up 12.3%, at $84.28, in recent trading. Moderna held an investor call Wednesday morning on the New England Journal paper, and on its plans for the Phase 3 trial of the vaccine set to begin July 27. Analysts said that the data from the Phase 1 trial was positive, but warned that the efficacy and safety of the vaccine was far from proven. A Phase 2 study of the vaccine is ongoing. "While a meaningful step forward, we stress this is still far from a done deal," wrote J.P. Morgan analyst Cory Kasimov in his own Tuesday night note. Kasimov noted that much remains unknown about how useful the vaccine will prove to be in protecting against Covid-19 infection. He noted that questions remain about how important neutralizing antibody levels are and how important T-cell responses are, among other things. SVB Leerink analyst Geoffrey Porges, in a Wednesday morning note, noted the high levels of fevers, chills, and other reactions reported by patients in the trial. "There is no doubt that this vaccine, like its competitors, will face challenges clinically and commercially if the same rates of local and systemic reactions persist, or increase, in their pivotal trial cohort," Porges wrote. "If they are offset by very strong disease prevention benefits, then these events are likely to be acceptable, but if not, or if they become more severe, they could significantly limit the vaccine's adoption in healthy and low risk individuals." It is tempting to try to make comparisons between the reported effectiveness seen in the clinical trials of the Moderna vaccine and the experimental Pfizer (PFE) vaccine, both of which use the same messenger RNA-based approach. Detailed Phase 1 data is now available on both of the vaccines. But Porges noted that because the trials used different tests, it's very hard to say if one or the other is better. "Due to differences in assays, it is very difficult to compare across trials; using the publications' own convalescent sera panels as controls, we aren't inclined to conclude that either the Moderna or Pfizer/BioNTech vaccines construct is better, or more immunogenic, than the other at this stage," he wrote. Write to Josh Nathan-Kazis at [email protected] (END) Dow Jones Newswires July 15, 2020 10:13 ET (14:13 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.
As of May 2020, no mRNA drug has been approved for human use. I invest by buying and holding. I want companies which actually have a product. Personal feeling is that Moderns and Inovio will not produce a vaccine. If a vaccine develops , it will come from a company which has already brought drugs to market. Without naming names, I won't speculate on a car company without a car. But for traders, Moderns offers all the thrills of hype and gains in stock value. If you can buy and sell with precision, there is money on the board. Obviously, someone is buying it. Not me. But people buy stock in empty cruise ships and empty theaters. There's something for everyone in the market.
when you will finaly see that Moderna´s product isn´t as good as Biontech´s (Pfizer) who are even deliver to China?
There's an old adage. "Buy the rumor, sell the news". I think that's a lot of it. There's also reports of a "mutation" in the vaccine in the UK so it could be fear about the vaccine no longer being effective. Could be lots of things.
I am in Moderna, I expect it to run into earnings at the end of the month and hopefully post strong earnings. Moderna to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 25, 2021 (yahoo.com) Also if they get approval on more doses per vial that could help too Moderna Could Boost Vaccine Supply by Adding Doses to Vials - The New York Times (nytimes.com)
I wonder how much more room this has. Once it reaches full FDA approval, I'd venture that 90% of businesses will start mandating vaccines to their employees. Some already have, and other large ones have stated that they're waiting for full FDA approval and then they will. I think Home Depot was on that line of talk.
Excellent point. United Airlines recently announced that all employees must be vaccinated. Personally, I wish -my- job would mandate as there's a handful of "HOAX!" people here.
This is going to be interesting cause if they get approval from the FDA then the drug approval game is really rigged.
I think it's more than COVID driven as well. Thought the vaccine is a bigger driver MRNA has a solid pipeline of other drugs. “Moderna has one of the world’s largest and most innovative vaccine development pipelines” … “We believe we have a unique opportunity to develop new vaccines against viruses hurting people around the world, at a pace that is radically different from what the industry has previously done” - company CEO Stéphane Bancel - Source
Please don't forget to pick up your free refill of "KOOL AID" down aisle 4 Lex Luger have a nice day.
